MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurof...

Descripción completa

Detalles Bibliográficos
Autor principal: Harder, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/
https://www.ncbi.nlm.nih.gov/pubmed/33863389
http://dx.doi.org/10.1186/s40364-021-00281-0
_version_ 1783679975248887808
author Harder, Anja
author_facet Harder, Anja
author_sort Harder, Anja
collection PubMed
description MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurofibromas in NF1. Targeting other lesions being associated with a high morbidity in NF1 seems to be promising. Due to involvement of multiple pathways in NF2 associated lesions as well as in malignant tumors, MEKi are also used in combination therapies. This review outlines the current state of MEKi application in neurofibromatosis and associated benign and malignant lesions.
format Online
Article
Text
id pubmed-8052700
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80527002021-04-19 MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions Harder, Anja Biomark Res Review MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurofibromas in NF1. Targeting other lesions being associated with a high morbidity in NF1 seems to be promising. Due to involvement of multiple pathways in NF2 associated lesions as well as in malignant tumors, MEKi are also used in combination therapies. This review outlines the current state of MEKi application in neurofibromatosis and associated benign and malignant lesions. BioMed Central 2021-04-16 /pmc/articles/PMC8052700/ /pubmed/33863389 http://dx.doi.org/10.1186/s40364-021-00281-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Harder, Anja
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title_full MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title_fullStr MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title_full_unstemmed MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title_short MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
title_sort mek inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/
https://www.ncbi.nlm.nih.gov/pubmed/33863389
http://dx.doi.org/10.1186/s40364-021-00281-0
work_keys_str_mv AT harderanja mekinhibitorsnoveltargetedtherapiesofneurofibromatosisassociatedbenignandmalignantlesions

Ejemplares similares